No profile data available.
Denali Therapeutics Inc. (DNLI) is a healthcare company in the brain and nerve treatment drugs industry, based in South San Francisco, United States, with about 503 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$512.54 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $3.60 million. Its market capitalization was $3.11 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Denali Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $3.60 million.
$3.11 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Edgewise Therapeutics, Inc. (EWTX), Xenon Pharmaceuticals Inc. (XENE), Acadia Pharmaceuticals Inc. (ACAD), Dyne Therapeutics, Inc. (DYN).